<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444765</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0496</org_study_id>
    <nct_id>NCT04444765</nct_id>
  </id_info>
  <brief_title>Hemodynamic and Respiratory Tolerance of Intermittent Hemodialysis in Critically Ill Patients</brief_title>
  <acronym>COOBrA</acronym>
  <official_title>Hemodynamic and Respiratory Tolerance of Intermittent Hemodialysis (Acetate Free Biofiltration and Bicarbonate-based Intermittent Dialysis) in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) affects up to 30% of critically ill patients and is associated with
      increased rates of mortality. Up to 60% of patients with AKI will ultimately require renal
      replacement therapy (RRT). Intermittent hemodialysis (IHD) is one of the main methods of RRT
      worldwide. In IHD-bicar, dialysate is composed by electrolytes, including calcium, and
      bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with
      acids (citric acid, chloride acid or acetic acid). However, IHD-bicar may be associated with
      hemodynamic instability or respiratory intolerance, mainly related to the CO2 release in the
      circulation during IHD (HCO3- &lt;--&gt; CO2 + H2O). Some recent studies showed that acetate free
      biofiltration (AFB-K), a technique that does not require dialysate acidification, could be
      associated with better hemodynamic stability and to a lower amount of CO2 delivered to the
      patients. AFB-K may thus improve the hemodynamic and respiratory tolerance of intermittent
      RRT in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational study, investigators aim to characterize the hemodynamic
      and respiratory tolerances of HDI-bicar and AFB-K in critically ill patients requiring RRT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of hemodynamic event</measure>
    <time_frame>From admission to discharge, up to 4 hours</time_frame>
    <description>The occurrence of at least one of the following events will be considered a hemodynamic event :
Hypotension (decrease of systolic or mean blood pressures ≥ 15 and ≥ 10% respectively)
Tachycardia (increase of heart beating ≥ 20%)
Cardiac arrythmia (junctional tachycardia, atrial fibrillation, flutter, ventricular tachycardia or fibrillation)
Decrease of the cardiac output ≥ 15% (only in patients with invasive cardiac output monitoring)
Starting (or increase dosing) of norepinephrine ≥ 0.1 µg/kg/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in maximal PaCO2</measure>
    <time_frame>1 hour after the beginning of dialysis , up to 4 hours</time_frame>
    <description>Evaluation of PaCO2 by arterial blood gas test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum difference of tcPCO2 and etCO2</measure>
    <time_frame>From admission to discharge, up to 4 hours</time_frame>
    <description>Evaluation of TcPCO2 and etCO2 by trans-cutaneous measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the &quot;strong ion difference&quot;</measure>
    <time_frame>baseline, 4 hours</time_frame>
    <description>Evaluation of the &quot;strong ion difference&quot; by blood ionogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma pH</measure>
    <time_frame>1 hour after the beginning of dialysis session, up to 4 hours</time_frame>
    <description>Evaluation of plasma pH by blood ionogram</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Patients with bicarbonate-based intermittent dialysis</arm_group_label>
    <description>Dialysate is composed by electrolytes, including calcium, and bicarbonate. To avoid calcium carbonate precipitation, dialysate has to be supplemented with acids (citric acid, chloride acid or acetic acid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with acetate free biofiltration dialysis</arm_group_label>
    <description>Acetate free biofiltration (AFB-K)is a technique that does not require dialysate acidification</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of clinical and biological data during renal replacement therapy sessions</intervention_name>
    <description>Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).</description>
    <arm_group_label>Patients with acetate free biofiltration dialysis</arm_group_label>
    <arm_group_label>Patients with bicarbonate-based intermittent dialysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute kidney injury
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years old

          -  Invasive monitoring of blood pressure

          -  Non opposition to the research

          -  Admission to the intensive care unit

          -  Need of intermittent hemodialysis

        Exclusion Criteria:

          -  Sodium bicarbonate infusion

          -  Pregnancy or breastfeeding

          -  Juridical protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanislas Faguer, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Stanislas Faguer, MD</last_name>
    <phone>05 61 32 24 75</phone>
    <phone_ext>+33</phone_ext>
    <email>faguer.s@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stanislas Faguer, MD</last_name>
      <phone>05 61 32 24 75</phone>
      <phone_ext>+33</phone_ext>
      <email>faguer.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute kidney injury</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>acetate free biofiltration</keyword>
  <keyword>bicarbonate-based hemodialysis</keyword>
  <keyword>C02 removal</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>critical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

